A Multiple-dose, Subject- and Investigator-blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Canakinumab (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 18 Sep 2017 Planned End Date changed from 1 Jul 2018 to 23 Jul 2019.
- 18 Sep 2017 Planned primary completion date changed from 1 Jul 2018 to 17 Sep 2018.
- 18 Sep 2017 Status changed from not yet recruiting to recruiting.